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1. Introduction 
1.1 2-adrenoceptor agonists and asthma 
The adrenergic receptors (adrenoceptors) are a member of the G protein-coupled receptor 
superfamily of membrane proteins that are targets of the catecholamines, norepinephrine 
and epinephrine. To date, two main groups of adrenoceptors,  and , with several subtypes 
have been identified. Many types of cells possess these receptors, and the binding of an 
agonist will generally cause a sympathetic response. Among them, 2-adrenoceptor agonists 
(2-agonists) are widely used as bronchodilators in the treatment of bronchial asthma 
because of their potent bronchodilating effects on airway smooth muscle. In addition to 
being bronchodilators, they may also have anti-inflammatory properties, including 
inhibition of granulocyte functions (Yasui et.al., 2006). However, concerns have been raised 
regarding the use of 2-agonists on a regular daily basis rather than only as needed for 
rescue therapy. More specifically, continuous and repetitive 2-agonist monotherapy has 
been considered to be associated with an increase in the degree of allergic inflammation 
(Cockcroft et.al., 1995), poor asthma outcomes (Paris et.al., 2008) and an increase in the risk 
of asthma death (Crane et.al., 1989; Nelson et.al., 2006). Although the precise molecular 
mechanisms underlying these undesirable effects of 2-agonists are not fully understood, 
several studies have independently demonstrated that 2-agonists have the potential to 
increase Th2 cytokine-mediated inflammation both in vivo and in vitro. For instance, 
Coqueret et.al. demonstrated that ovalbumin-sensitized mice treated with a daily injection 
of salbutamol showed increased anti-ovalbumin IgE levels in their serum, probably due to 
increased production of Th2 cytokines (Coqueret et.al., 1994). Panina-Bordignon et.al. 
demonstrated that 2-agonists prevented Th1 development by selectively inhibiting IL-12 
production (Panina-Bordignon et.al., 1997). More recently, Loza et.al. demonstrated that 
human Th2 cells express 2-adrenergic receptor and that 2-agonists augmented the 
accumulation of Th2 cells in human peripheral blood lymphocyte cultures subjected to 
bystander stimuli (Loza et.al., 2007). These findings suggest a mechanism by which 2-
agonist monotherapy may favor Th2 immune responses, which are believed to be involved 
in the pathogenesis of asthma. 
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1.2 TSLP and asthma 
Thymic stromal lymphopoietin (TSLP) is an IL-7-like cytokine which was originally 
identified in the supernatant of a murine thymic stromal cell line (Friend et.al., 1994). 
Increasing evidence suggests that TSLP plays important roles in the pathogenesis of allergic 
diseases such as asthma and atopic dermatitis (Al-Shami te.al., 2005; Yoo et.al., 2005). The 
most clinically relevant role of TSLP is mediated by dendritic cells (DCs) through induction 
of OX40 ligand expression on DCs (Ito et.al., 2005; Liu, 2007a). Naïve T cells receiving 
antigen-presentation from TSLP-primed DCs develop into Th2 cells that produce IL-4, -5, -
13 and TNF- but not IL-10 (Ito et.al., 2005; Liu, 2007a; Soumelis et.al., 2002). These Th2 cells 
are now referred as to “inflammatory Th2 cells” in consideration of their potential for 
releasing the proinflammatory cytokine, TNF-, in addition to Th2 cytokines (Orihara et.al.; 
2008). Furthermore, mice with transgenic overexpression of TSLP in the lung develop severe 
airway inflammation, including massive infiltration by inflammatory cells, goblet cell 
hyperplasia and airway hyperresponsiveness (Zhou et.al., 2005). Mice with transgenic 
overexpression of TSLP in skin keratinocytes develop severe dermatitis with itching, which 
is similar to the clinical features of atopic dermatitis in humans (Yoo et.al., 2005). On the 
other hand, mice lacking the TSLP receptor exhibit strong Th1 responses and fail to develop 
an inflammatory lung response to antigens (Al-Shami te.al., 2005). Thus, TSLP is an 
important cytokine that is necessary and sufficient for initiation of allergic inflammation. 
2. The enhancing effect of 2-adrenoceptor agonists on cytokine-induced 
TSLP production by human lung tissue cells 
2.1 Cytokine-induced production of TSLP by lung tissue cells 
It is widely accepted that TSLP is expressed predominantly in epithelial cells of the lung, 
intestine and skin keratinocytes (Soumelis et.al., 2002; Liu et.al., 2007b). We confirmed an 
earlier report (kato et.al., 2007) that a combination of IL-4 and TNF- synergistically induced 
TSLP production by normal human bronchial epithelial cells (NHBE) (Fig. 1A). Unlike 
NHBE, lung mesenchymal cells such as bronchial smooth muscle cells (BSMC) and normal 
human lung fibroblasts (NHLF) produced TSLP in response to TNF-, but not IL-4 alone. 
However, like NHBE, those cells produced greater amounts of TSLP as a result of 
synergistic effects between IL-4 and TNF- (Fig. 1B and 1C). Of note, these mesenchymal 
cells produce appreciable amounts of TSLP compared to NHBE, suggesting the possibility 
that lung mesenchymal cells are, like epithelial cells, important cellular sources of TSLP. 
2.2 Effects of 2-agonists on cytokine-induced TSLP production 
We next examined the effects of 2-agonists on the cytokine-induced TSLP production by the 
human lung tissue cells. Although 2-agonists act mainly on airway smooth muscle as 
bronchodilators, they are also known to express anti-inflammatory effects on granulocytes 
(Yasui et.al., 2006), epithelial cells (Koyama et.al., 1999) and fibroblasts (Spoelstra et.al., 2002). 
As shown in Fig 2A, when NHBE were stimulated with a combination of IL-4 and TNF-, 
simultaneous addition of various concentrations of two long-acting 2-agonists, i.e., salmeterol 
and formoterol, and a short-acting 2-agonist, salbutamol, showed significant enhancement of 
the cytokine-induced TSLP production. Optimal concentrations of these 2-agonists were 
employed, and then the mRNA expression of TSLP in NHBE was measured by quantitative 
real-time PCR. TSLP mRNA expression was significantly enhanced by 10-10 M salmeterol, 10-10 
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M formoterol and 10-8 M salbutamol (Fig. 2B), suggesting that the enhancing effects of 2-
agonists on TSLP production were transcriptionally-regulated. It should be noted that 2-
agonists enhanced TSLP production by airway smooth muscle cells and lung fibroblasts as 
well as bronchial epithelial cells (Fig. 2C and 2D). We suppose that the production of TSLP by 
these lung tissue cells is particularly important because dendritic cells have to migrate through 
these airway interstitial cells to lymphopoietic tissues in order to present antigen information 
to naïve T cells. Therefore, enhanced TSLP production by lung tissue cells in response to 2-
agonists may lead to exacerbation of allergic airway inflammation, and this may partly explain 
the undesirable clinical effects of continuous 2-agonist monotherapy. 
 
 
Fig. 1. Cytokines induce production of TSLP by lung tissue cells. NHBE (A), BSMC (B) and 
NHLF (C) were treated with 10 ng/ml IL-4 alone, 10 ng/ml TNF- alone and a combination 
of both for 48 h. TSLP concentrations in the culture supernatants were quantified by ELISA. 
Data are shown as the mean ± SD of quadruplicate samples and are representative of at least 
three separate experiments. ** p < .01 compared with unstimulated control. Reprinted from 
Futamura et. Al., 2010. 
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Fig. 2. 2-agonists enhance cytokine-induced TSLP production by lung tissue cells. (A) 
NHBE were treated with different concentrations of two long-acting 2-agonists, salmeterol 
(SM) and formoterol (FM), or a short-acting 2-agonist, salbutamol (SB), in the presence of 10 
ng/ml IL-4 and 10 ng/ml TNF- for 48 h. TSLP concentrations in the culture supernatants 
were quantified by ELISA. (B) NHBE were treated with cytokines at 10 ng/ml in the 
presence and absence of the indicated concentrations of each 2-agonist (SM, FM, SB) for 6 h. 
The copy numbers of TSLP mRNA are shown. BSMC (C) and NHLF (D) were treated with 
the indicated concentrations of each 2-agonist (SM, FM, SB) in the presence of 10 ng/ml IL-
4 and 10 ng/ml TNF- for 48 h. TSLP concentrations in the culture supernatants were 
quantified by ELISA. All data are shown as the mean ± SD of quadruplicate samples and are 
representative of at least three separate experiments. ** p < .01 compared with IL-4 plus 
TNF-. Reprinted from Futamura et. Al., 2010. 
2.3 Effects of cAMP-elevating agents on cytokine-induced TSLP production 
It is well known that binding of 2-agonists to 2-adrenoceptors activates adenylate cyclase, 
resulting in generation of intracellular cAMP. We therefore examined the role of 
intracellular cAMP in the enhancement of TSLP production. The cells were stimulated with 
three cAMP-elevating agents, i.e., 8-bromoadenosine cyclic monophosphate, dibutyryl 
adenosine cyclic monophosphate (hereinafter referred to as 8-Br cAMP and db cAMP, 
respectively) and forskolin (an adenylate cyclase activator). All three agents caused 
significant enhancement of cytokine-induced TSLP production by the lung tissue cells (Fig. 
3). These results suggest that the enhancing effects of 2-agonists on TSLP production were 
mediated via upregulation of intracellular cAMP in these cells.  
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Fig. 3. Intracellular cAMP-elevating agents enhance cytokine-induced TSLP production by 
lung tissue cells. NHBE (A), BSMC (B) and NHLF (C) were treated with 10 ng/ml IL-4 and 
10 ng/ml TNF- in the presence and absence of the indicated concentrations of each cAMP-
elevating agent (8-Br cAMP, db cAMP, forskolin) for 48 h. TSLP concentrations in the 
culture supernatants were quantified by ELISA. Data are shown as the mean ± SD of 
quadruplicate samples and are representative of at least three separate experiments. * p < .05 
and ** p < .01 compared with IL-4 plus TNF-. Reprinted from Futamura et. Al., 2010. 
2.4 Effects of corticosteroid on cytokine-induced TSLP production 
According to the recently updated guidelines for asthma management, the preferred treatment 
regimen for patients with intermittent asthma is an inhaled short-acting 2-agonist, and the 
next step regimen is additional treatment with an inhaled corticosteroid. Therefore, we 
examined the effects of a corticosteroid, fluticasone, on the 2-agonist-induced increase in 
TSLP production. Simultaneous addition of various concentrations of fluticasone caused dose-
dependent, significant inhibition of both cytokine-induced (closed squares) and salmeterol-
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enhanced (closed triangles) TSLP production by NHBE (Fig. 4A, upper graph). Similar results 
were obtained in experiments using NHLF (Fig. 4A, lower graph) and BSMC (data not  
 
 
Fig. 4. Fluticasone inhibits TSLP production without affecting the intracellular cAMP level. (A) 
NHBE (upper graph) and NHLF (lower graph) were treated with 10 ng/ml IL-4 and 10 ng/ml 
TNF- with and without 10-10 M salmeterol (SM) for 48 h. The effects of simultaneous addition 
of the indicated concentrations of fluticasone on the TSLP production are shown. Data are 
shown as the mean ± SD of quadruplicate samples and are representative of at least three 
separate experiments. * p < .05 and ** p < .01 compared to without fluticasone. (B) NHBE were 
treated with 10 ng/ml IL-4 and 10 ng/ml TNF- with and without a 2-agonist (10-10 M SM, 10-
8 M SB) for 5 min. The effects of simultaneous addition of 10-8 M fluticasone on the intracellular 
cAMP levels are shown. Data are shown as the mean ± SD of triplicate samples and are 
representative of three separate experiments. Reprinted from Futamura et. al., 2010. 
www.intechopen.com
2-Adrenoceptor Agonists and Allergic Disease: The Enhancing Effect of 
2-Adrenoceptor Agonists on Cytokine-Induced TSLP Production by Human Lung Tissue Cells 409 
shown). Importantly, simultaneous treatment at the highest concentration of fluticasone  
(10-8 M), which can still considered to be clinically feasible, almost completely abrogated not 
only the cytokine-induced TSLP production but also the enhancement by the 2-agonists.  
2.5 Corticosteroid inhibition of TSLP production is not due to direct inhibition of 
cAMP signaling 
In order to clarify how corticosteroids might inhibit TSLP production, we examined the 
effects of fluticasone and 2-agonists on the intracellular cAMP level in NHBE. Addition of 
salmeterol or salbutamol significantly increased the cAMP level after 5 minutes of 
incubation. Addition of 10-8 M fluticasone showed no effect on the intracellular cAMP level 
whether in the presence or absence of a 2-agonist (Fig. 4B), indicating that corticosteroid 
inhibition of TSLP production is not due to direct inhibition of cAMP signaling. These 
results also suggest that corticosteroids inhibit TSLP synthesis by acting on the downstream 
signaling pathway of cAMP. 
To date, several mechanisms have been proposed to explain the synergistic action between 
corticosteroids and 2-agonists: induction and protection of 2-adrenoceptors by 
corticosteroids (Barnes, 2002), enhancement of translocation of glucocorticoid receptors into 
the nucleus by 2-agonists (Usami et.al., 2005) and post-transcriptional regulation to 
suppress expression of inflammatory genes (Kaur et.al., 2008). Our results may shed new 
light on the mechanisms by which combination therapy using an inhaled 2-agonist and an 
inhaled corticosteroid shows synergistic clinical efficacy in patients with asthma. 
3. Future challenges 
It remains to be clarified whether the enhancing effect of 2-agonists on cytokine production 
is specific to TSLP or not. Koyama et. al. demonstrated that TNF--induced production of 
granulocyte-macrophage colony-stimulating factor (GM-CSF), CCL5 and IL-8 by a human 
bronchial epithelial cell line, BEAS-2B, was significantly inhibited by procaterol, a 2-agonist 
(Koyama et. al., 1999). We confirmed that the cytokine-induced production of GM-CSF and 
CCL5, but not IL-8, by NHBE was significantly suppressed by 2-agonist treatment (data not 
shown). On the other hand, it was reported that rhinovirus-induced IL-6 production by 
NHBE was increased by salmeterol (Edwards et. Al., 2007), and we also found that the 
cytokine-induced production of IL-6 as well as TSLP by NHBE was significantly enhanced 
by simultaneous treatment with 2-agonists (data not shown). Thus, 2-agonists are able to 
crucially modulate the production of various inflammatory mediators through mechanisms 
that need to be further elucidated. 
4. Conclusion 
In this study, we focused on the effects of 2-agonists on the in vitro synthesis of TSLP, 
which is a key cytokine in the development of allergic diseases. We found that 2-agonists 
significantly enhanced cytokine-induced TSLP production by cultured primary human lung 
tissue cells. This enhancement may be partly responsible for the undesirable clinical effects 
of continuous 2-agonist monotherapy, and our other findings suggest that combination 
therapy with a corticosteroid might effectively inhibit TSLP-mediated allergic inflammation. 
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